The latest news: Combination of OptuneŽ with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients The 5 year results for Optune just came out and they were unbelievably good. This is a large study in newly diagnosed GBM patients so the results are significant. Bottom line: 5 year survival rate was 13% for the Optune (plus Temodar) group and only 5% for the Temodar alone group. That is a major step forward. How the poliovirus can be used to battle lethal cancers This is one of the more exciting experimental treatments in the pipeline. We (the Musella Foundation) has funded a small part of it! BrainTumor Co-Payment Assistance Program Status: OPEN to new applicants
